Overview

A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast cancer. The study will also assess the safety of this combination treatment.
Phase:
Phase 2
Details
Lead Sponsor:
R-Pharm
Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Epothilones
Paclitaxel